Novartis Foradil Aerolizer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The selective beta2 agonist is expected to launch in May or June, according to Novartis. Formoterol was approved Feb. 16 for maintenance treatment of asthma and prevention of bronchospasm in adults and children 5 years and older with reversible obstructive airway disease. The product also was cleared for "acute prevention of exercise-induced bronchospasm" in patients 12 years and older. Phase IV commitments include a study of higher doses of Foradil that is expected to start by February 200